Effectiveness and Tolerability Profile of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes

被引：0
|
作者：
Gorgojo-Martinez, Juan J.
Feo-Ortega, Gara
Serrano-Moreno, Clara
Sanz-Velasco, Alberto
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2264-PUB
引用
收藏
页码：A573 / A573
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Capel, M.
    Ciudin, A.
    Mareque, M.
    Rodriguez, R. M.
    Oyaguez, I
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [22] EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Ashley, D.
    Vega, G.
    Hunt, B.
    Valentine, W. J.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [23] GLP-1 Agonists: Improving the Future of Patients With Type 2 Diabetes
    Shubrook, Jay H.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2011, 111 (02): : ESII - ES1
  • [24] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina M.
    Marsolo, Keith
    Bosworth, Hayden B.
    Pagidipati, Neha
    DIABETES, 2024, 73
  • [25] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [26] Baseline Characteristics of Patients with Type 2 Diabetes Initiating Sitagliptin or GLP-1 Receptor Agonists
    Brodovicz, Kimberly G.
    Ritchey, Mary E.
    Chen, Yong
    Senderak, Michael
    Liao, Jane
    Girman, Cynthia J.
    Shankar, Ravi
    Liu, Zhiwen
    Engel, Samuel S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 196 - 196
  • [27] Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists
    Garcia de Lucas, M. D.
    Olalla Sierra, J.
    DIABETES & METABOLISM, 2017, 43 (04) : 373 - 374
  • [28] GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
    Marx, Nikolaus
    Husain, Mansoor
    Lehrke, Michael
    Verma, Subodh
    Sattar, Naveed
    CIRCULATION, 2022, 146 (24) : 1882 - 1894
  • [29] GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
    Monney, Marine
    Jornayvaz, Francois R.
    Gariani, Karim
    DIABETES & METABOLISM, 2023, 49 (05)
  • [30] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    Juris J. Meier
    Nature Reviews Endocrinology, 2012, 8 : 728 - 742
12345